Search research articles
Contact Us
Filters
Showing results (31-40 of 52) with videos related to
Page
of 6
Sort By:
Nuclear Medicine and Biology
|
January 10, 2012
64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer
Andrew B Jackson, Prasant K Nanda, Tammy L Rold, et al.
Molecular Imaging
|
May 30, 2007
In vitro and in vivo evaluation of Alexa Fluor 680-bombesin[7-14]NH2 peptide conjugate, a high-affinity fluorescent probe with high selectivity for the gastrin-releasing peptide receptor
Lixin Ma, Ping Yu, Bhadrasetty Veerendra, et al.
Nuclear Medicine and Biology
|
December 3, 2014
Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy
Tamila J Stott Reynolds, Rebecca Schehr, Dijie Liu, et al.
In Vivo (Athens, Greece)
|
July 10, 2012
Positron-emission tomography (PET) imaging agents for diagnosis of human prostate cancer: agonist vs. antagonist ligands
Prasant K Nanda, Brieanne E Wienhoff, Tammy L Rold, et al.
Anaerobe
|
September 10, 2010
Genetic analysis of mobile tetQ elements in oral Prevotella species
Gena D Tribble, John J Garza, Victor L Yeung, et al.
Bioconjugate Chemistry
|
June 12, 2010
Comparative evaluation of three 64Cu-labeled E. coli heat-stable enterotoxin analogues for PET imaging of colorectal cancer
Dijie Liu, Douglas Overbey, Lisa D Watkinson, et al.
Bioconjugate Chemistry
|
March 22, 2007
In vitro and in vivo evaluation of a novel 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys)
Susana Alves, João D G Correia, Lurdes Gano, et al.
Cancers
|
June 20, 2019
PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer
Yariswamy Manjunath, Sathisha V Upparahalli, Diego M Avella, et al.
Nuclear Medicine and Biology
|
June 22, 2018
Matched-pair, <sup>86</sup>Y/<sup>90</sup>Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer
Nilantha Bandara, Tamila J Stott Reynolds, Rebecca Schehr, et al.
In Vivo (Athens, Greece)
|
March 16, 2007
The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals
Adam F Prasanphanich, Stephanie R Lane, Said D Figueroa, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 52) with videos related to
Sort By:
Page
of 6
Nuclear Medicine and Biology
|
January 10, 2012
64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer
Andrew B Jackson, Prasant K Nanda, Tammy L Rold, et al.
Molecular Imaging
|
May 30, 2007
In vitro and in vivo evaluation of Alexa Fluor 680-bombesin[7-14]NH2 peptide conjugate, a high-affinity fluorescent probe with high selectivity for the gastrin-releasing peptide receptor
Lixin Ma, Ping Yu, Bhadrasetty Veerendra, et al.
Nuclear Medicine and Biology
|
December 3, 2014
Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy
Tamila J Stott Reynolds, Rebecca Schehr, Dijie Liu, et al.
In Vivo (Athens, Greece)
|
July 10, 2012
Positron-emission tomography (PET) imaging agents for diagnosis of human prostate cancer: agonist vs. antagonist ligands
Prasant K Nanda, Brieanne E Wienhoff, Tammy L Rold, et al.
Anaerobe
|
September 10, 2010
Genetic analysis of mobile tetQ elements in oral Prevotella species
Gena D Tribble, John J Garza, Victor L Yeung, et al.
Bioconjugate Chemistry
|
June 12, 2010
Comparative evaluation of three 64Cu-labeled E. coli heat-stable enterotoxin analogues for PET imaging of colorectal cancer
Dijie Liu, Douglas Overbey, Lisa D Watkinson, et al.
Bioconjugate Chemistry
|
March 22, 2007
In vitro and in vivo evaluation of a novel 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys)
Susana Alves, João D G Correia, Lurdes Gano, et al.
Cancers
|
June 20, 2019
PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer
Yariswamy Manjunath, Sathisha V Upparahalli, Diego M Avella, et al.
Nuclear Medicine and Biology
|
June 22, 2018
Matched-pair, <sup>86</sup>Y/<sup>90</sup>Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer
Nilantha Bandara, Tamila J Stott Reynolds, Rebecca Schehr, et al.
In Vivo (Athens, Greece)
|
March 16, 2007
The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals
Adam F Prasanphanich, Stephanie R Lane, Said D Figueroa, et al.
Page
of 6